In Part I, we argued that static KOL lists can’t keep up with how influence actually moves. Part II focuses on what happens next: how advocacy must evolve across the lifecycle without losing what matters most: clinical credibility, judgement, and trust.
At the start of a new year, many teams default to what feels safe.
The same expert roster.
The same congress moments.
The same hierarchy of messages.
The same internal dashboards.
It’s understandable. It’s easy to justify. And it often looks reassuringly consistent.
But consistency is not the same as progress.
In January (Part I), we made the case for moving beyond static KOL lists toward a living influence system anchored in clinical excellence. Visibility is easier to document than influence and lists rarely capture how trust forms or how decisions really get made.
The harder question is what comes next.
Because most advocacy drift doesn’t happen due to lack of effort. It happens at lifecycle transition points, when the science is still strong, but the decision dynamics have changed.
What follows is a practical reframing of what must evolve as a product moves from innovation to scale to maturity, while keeping the non-negotiables intact.
1. The Core Mistake: Treating Advocacy as a Repeatable Program
Many advocacy programs are built like engines you expect to run indefinitely: a fixed cadence, a familiar faculty, predictable outputs.
That approach can work, until it doesn’t.
What usually happens isn’t dramatic. The program still looks active. Events still happen. Content still ships. Senior experts still participate. Internally, the plan feels solid because it’s measurable and consistent.
And yet, in the market, momentum stalls.
Conversations don’t deepen. Objections persist. Behavior changes slowly, if at all.
Often, the issue isn’t the science. It’s that the program hasn’t moved with the lifecycle realities shaping adoption today.
“I value the insights from senior experts, but if the message still feels tailored to academics, it won’t help me address the realities of my clinic.”
Dr. Tanya Trin, MD BAppSc MBBS FRANZCO
That single insight is often the difference between activity and impact.
2. Three Lifecycle Phases That Demand Different Advocacy
A lifecycle lens isn’t a marketing exercise. It’s a decision lens.
The point isn’t whether a product is “new” or “old.” It’s understanding how barriers to adoption and the type of confidence clinicians need shift over time.
Early Innovation: Confidence, Boundaries, Appropriate Use
Early-stage advocacy is about credible reassurance.
Not hype.
Not volume.
Not visibility for its own sake.
Clinicians are asking:
- Is the evidence solid and relevant?
- Who is this really for and who is it not for?
- What does appropriate use look like in real practice?
- What are the trade-offs, complications, and learning curve?
Here, expert voices establish confidence, define boundaries, and translate novelty into something peers can trust. What matters is judgment, rigor, and real-world relevance.
Scale: Implementation, Workflow Confidence, Normalization
Once a product is no longer truly “new,” awareness is rarely the barrier.
What holds adoption back are practical realities: workflow pressure, training capacity, service constraints, and whether clinicians believe this will work on a busy Monday morning.
At this stage, influence shifts quietly. The most impactful voices are often the least visible:
- Practical guidance that fits existing pathways
- Training models that feel realistic
- Answers to “how do we do this here?” rather than “why should we do this?”
If the influence architecture doesn’t shift here, engagement can stay busy while impact flattens.
Maturity: Relevance, Renewal, and the Legacy Voice Problem
Mature products often assume adoption is earned.
The evidence exists. Relationships are established. Congress presence is familiar.
And yet momentum can stall, sometimes more frustratingly than at launch.
Maturity is where relevance matters most. Not because expertise matters less, but because clinical reality keeps changing. New pressures emerge. New decision-makers enter the system. New peer networks form.
If advocacy doesn’t evolve with those realities, it slowly loses pull.
3. Why Mature Products Stall Even with Strong Science
When mature advocacy underperforms, the cause is usually unglamorous: over-reliance on legacy relationships and static engagement models.
The same senior voices.
Used the same way.
For the same audiences.
Year after year.
What once built credibility can become background noise not because the experts aren’t respected, but because the engagement no longer addresses today’s barriers.
Meanwhile, the system moves on: outcomes pressure, staffing constraints, workflow redesign, new peer dynamics.
“I respect the professors. But if it still sounds like it’s for professors, it won’t change what happens in my clinic.”
Francesco Carones
That’s not a criticism of senior experts. It’s a warning about program design.
A simple diagnostic question is revealing:
If the product is established but adoption isn’t where it should be, have the relationships evolved or have they just been repeated?
The right voice is not a title. It’s trusted clinical judgment in context.
4. Authority vs. Practice Leadership: “Right Expert” Changes by Stage
One reason lifecycle-aligned advocacy is hard is that many teams use a single definition of “the right expert.”
In reality, “right” depends on the barrier you’re trying to move.
It helps to separate three roles that often get conflated:
Authority (Credibility and Standards)
Senior experts anchor credibility. They define standards, interpret evidence, and establish appropriate use especially critical early.
Practice Leadership (Translation into Routine)
These are the clinicians closest to implementation: trainers, service leads, and trusted problem-solvers. They answer the questions that determine whether adoption happens.
Connectors (Movement Across Communities)
Connectors bridge subspecialties, practice settings, generations, and care settings. They help ideas travel and consensus form.
The goal isn’t to replace authority. It’s to complement it with the expertise that makes change workable.
5. A Practical Example: Governance That Evolves
Earlier in my career, I led a regional steering panel in Asia designed to support professional education across multiple markets.
The panel was intentionally built with a rule that felt uncomfortable at first: it would repeat annually, but with new members each year.
Not because the prior experts lacked value but because perspectives, system pressures, and educational needs change quickly. Fresh membership ensured relevance, reduced echo chambers, and created space for emerging leaders while still anchoring on high standards.
Over time, something important happened. The program became the constant not the names. Credibility endured because governance was intentional, renewal was built in, and expertise stayed aligned with real-world needs.
That experience reinforced a simple truth: resilience doesn’t come from static rosters. It comes from influence patterns that can adapt.
6. From “Names” to Ecosystem
Names change. Roles shift. Availability fluctuates. New voices emerge.
A list built around a few familiar names may look strong, but it’s fragile.
What endures are influence patterns:
- Who peers trust
- How training truly happens
- Where clinical judgment gets pressure-tested
- Who helps ideas move between groups
Resilient advocacy ecosystems typically include:
- Senior authority (credibility)
- Practical implementers (translation)
- Emerging leaders (future bench)
- Connectors (diffusion)
This isn’t novelty for novelty’s sake. It’s making sure the right expertise is present for today’s decisions and tomorrows.
Stage → Needs → Voices
Early innovation → confidence / appropriate use → credible authorities + early
adopters
Scale → workflow / training / normalization → implementers + trainers + connectors
Maturity → relevance / renewal → refreshed mix + practice leaders
7. The Governance Advantage
Lifecycle-aligned engagement isn’t just more effective. It’s often more defensible.
Clear rationale for evolution reduces ad hoc decisions, documentation gaps, and visibility-led planning that looks robust internally but misses real adoption barriers.
In a regulated, relationship-driven specialty, credibility is capital. Governance is how you protect it.
8. Practical Takeaways
If you’re revisiting KOL engagement this year, five shifts matter:
- Treat lifecycle transitions as triggers to refresh advocacy
- Keep credibility constant; evolve translation
- Separate visibility from influence
- Build ecosystems, not rosters
- Measure confidence and behavior not just outputs
The most useful planning question for 2026 may be this:
As your product and market evolve, has your advocacy evolved with them or is it still optimized for a previous stage?
